Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02380677 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02380677 is a Phase 1 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 42 participants.
The verdict
NCT02380677, a Phase 1 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
A Phase 1/2a, open-label, dose-escalation study with enrollment in Phase 1 to continue until determination of the Maximum Tolerated Dose (MTD) /Recommended Phase 2a Dose (RP2D), and then enrollment into Phase 2a expansion cohorts will be initiated.
Interventions
- DRUG CRLX301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02380677
The ClinicalTrials.gov registry entry for NCT02380677 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CRLX301 is the first listed.
NCT02380677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02380677 about?
NCT02380677 is a clinical study titled "Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors". A Phase 1/2a, open-label, dose-escalation study with enrollment in Phase 1 to continue until determination of the Maximum Tolerated Dose (MTD) /Recommended Phase 2a Dose (RP2D), and then enrollment into Phase 2a expansion cohorts will be initiated.
What is the current status of trial NCT02380677?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2015-04. Estimated completion is 2017-10-04.
What interventions are being tested in trial NCT02380677?
The interventions under investigation include: CRLX301 (DRUG).
Who is sponsoring clinical trial NCT02380677?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.